AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06681324
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Phase 3
Recruiting
- Conditions
- Heart Failure
- Interventions
- Other: Placebo and dapagliflozin
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11300
- Registration Number
- NCT06677060
- Locations
- 🇻🇳
Research Site, Vinh Yen, Vietnam
Observational Study on the Treatment of Patients With Metastatic Breast Cancer
Recruiting
- Conditions
- Cancer
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06676436
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
Phase 1
Recruiting
- Conditions
- Chronic Kidney DiseaseAtherosclerotic Cardiovascular Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06675175
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Recruiting
- Conditions
- Heart DiseaseHeart FailureCardiovascular DiseaseHeart Failure, Systolic
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 438
- Registration Number
- NCT06675552
- Locations
- 🇩🇪
Research Site, Wuppertal, Germany
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
Phase 1
Completed
- Conditions
- Dyslipidaemia
- Interventions
- Drug: Ethinyl estradiol/levonorgestrel
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT06671405
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06673043
- Locations
- 🇵🇱
Research Site, Wroclaw, Poland
Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT06662123
- Locations
- 🇨🇳
Research Site, Wuhan, China
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06661733
- Locations
- 🇧🇬
Research Site, Sofia, Bulgaria
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 442
- Registration Number
- NCT06659029
- Locations
- 🇺🇸
Research Site, Las Vegas, Nevada, United States
© Copyright 2025. All Rights Reserved by MedPath